|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Perioperative thrombotic complications in liver transplantation显示文摘Although the perioperative bleeding complications and the major side effects of blood transfusion have always been the primary concern in liver transplantation(OLT),the possible cohesion of an underestimated intrinsic hypercoagulative state during and after the transplant procedure may pose a major threat to both patient and graft survival.Thromboembolism during OLT is characterized not only by a complex aetiology,but also by unpredictable onset and evolution of the disease.The initiation of a procoagulant process may be triggered by various factors,such as inflammation,venous stasis,ischemia-reperfusion injury,vascular clamping,anatomical and technical abnormalities,genetic factors,deficiency of profibrinolytic activity,and platelet activation.The involvement of the arterial system,intracardiac thrombosis,pulmonary emboli,portal vein thrombosis,and deep vein thrombosis,are among the most serious thrombotic events in the perioperative period.The rapid detection of occlusive vascular events is of paramount importance as it heavily influences the prognosis,particularly when these events occur intraoperatively or early after OLT.Regardless of the lack of studies and guidelines on anticoagulant prophylaxis in this setting,many institutions recommend such an approach especially in the subset of patients at high risk.However,the decision of when,how and in what doses to use the various chemical anticoagulants is still a difficult task,since there is no common consensus,even for highrisk cases.The risk of postoperative thromboembolism causing severe hemodynamic events,or even loss of graft function,must be weighed and compared with the risk of an important bleeding.In this article we briefly review the risk factors and the possible predictors of major thrombotic complications occurringin the perioperative period,as well as their incidence and clinical features.Moreover,the indications to pharmacological prophylaxis and the current treatment strategies are also summarized. | Paolo Feltracco Stefania Barbieri Umberto Cillo Giacomo Zanus Marco Senzolo Carlo Ori | 2015 | World Journal of Gastroenterology2015，21，26： | 13 |
| 2 | Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatoceiluiar carcinoma显示文摘AIM: To explore the potential prognostic role of preoperative tumor grade and blood AFP mRNA in a cohort of patients with hepatocellular carcinoma (HCC)eligible for radical therapies according to a well-defined treatment algorithm not including nodule size and number as absolute selection criteria.METHODS: Fifty patients with a diagnosis of HCC were prospectively enrolled in the study. Inclusion criteria were: (1) histological assessment of tumor grade by means of percutaneous biopsies; (2) determination of AFP mRNA status in the blood; (3) patient's eligibility for radical therapies.RESULTS: At preoperative evaluation, 54% of the study group had a well-differentiated HCC, 42% had AFP mRNA in the blood, 40% had a tumor larger than 5 cm and 56% had more than one nodule. Surgery (resection or liver transplantation) was performed in 29 patients,while 21 had percutaneous ablation procedures. After a median follow-up of 28 mo, 12-, 24-, and 36-mo survival rates were 78%, 58%, and 51%, respectively. Surgical therapy, performance status and three tumor-related variables (AFP mRNA, HCC grade and gross vascular invasion) resulted as significant survival predictors at univariate analysis. Nodule size and number did not perform as significant prognosticators. Multivariate study selected only surgical therapy and a biologically early HCC profile (AFP mRNA negative and well-differentiated tumor without gross vascular invasion) as independent survival variables.CONCLUSION: The preoperative determination of tumor grade and blood AFP mRNA status may potentially refine the prognostic evaluation of HCC patients and improve the selection process for radical therapies. | Umberto Cillo Alessandro Vitale Filippo Navaglia Daniela Basso Umberto Montin Marco Bassanello Francesco D'Amico Francesco Antonio Ciarleglio Alberto Brolese Giacomo Zanus Vito De Pascale Mario Plebani Davide Francesco D'Amico | 2005 | World Journal of Gastroenterology2005，11，44： | 12 |
| 3 | Covert hepatic encephalopathy: Agreement and predictive validity of different indices显示文摘AIM:To investigate the agreement and prognosticvalue of different measures of covert hepatic encephalopathy(CHE).METHODS:One-hundred-and-thirty-two cirrhotic outpatients underwent electroencephalography(EEG),paper-and-pencil psychometry(PHES)and critical flicker frequency,scored on the original/modified(CFFo/CFFm)thresholds.Eighty-four patients underwent Dopplerultrasound to diagnose/exclude portal-systemic shunt.Seventy-nine were followed-up for 11±7 mo in relation to the occurrence of hepatic encephalopathy(HE)-related hospitalisations.RESULTS:On the day of study,36%had gradeⅠHE,42%abnormal EEG,33%abnormal PHES and 31/21%abnormal CFFo/CFFm.Significant associations were observed between combinations of test abnormalities;however,agreement was poor(Cohen’sκ<0.4).The prevalence of EEG,PHES and CFFo/CFFm abnormalities was significantly higher in patients with gradeⅠovert HE.The prevalence of EEG and CFFm abnormalities was higher in patients with shunt.The prevalence of EEG abnormalities was significantly higher in patients with a history of HE.During follow-up,10 patients died,10were transplanted and 29 had HE-related hospitalisations.GradeⅠHE(P=0.004),abnormal EEG(P=0.008)and abnormal PHES(P=0.04)at baseline all predicted the subsequent occurrence of HE;CFF did not.CONCLUSION:CHE diagnosis probably requires a combination of clinical,neurophysiological and neuropsychological indices. | Sara Montagnese Esmeralda Balistreri Sami Schiff Michele De Rui Paolo Angeli Giacomo Zanus Umberto Cillo Giancarlo Bombonato Massimo Bolognesi David Sacerdoti Angelo Gatta Carlo Merkel Piero Amodio | 2014 | World Journal of Gastroenterology2014，20，42： | 6 |
| 4 | Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study显示文摘AIM To evaluate waiting list(WL) registration and liver transplantation(LT) rates in patients with hepatitis C virus(HCV)-related cirrhosis since the introduction of direct-acting antivirals(DAAs).METHODS All adult patients with cirrhosis listed for LT at Padua University Hospital between 2006-2017 were retrospectively collected using a prospectivelyupdated database; patients with HCV-related cirrhosis were divided by indication for LT [dec-HCV vs HCV/hepatocellular carcinoma(HCC)] and into two interval times(2006-2013 and 2014-2017) according to the introduction of DAAs. For each patient, indications to LT, severity of liver dysfunction and the outcome in the WL were assessed and compared between the two different time periods. For patients receiving DAA-based regimens, the achievement of viral eradication and the outcome were also evaluated. RESULTS One thousand one hundred and ninty-four [male(M)/female(F): 925/269] patients were included. Considering the whole cohort, HCV-related cirrhosis was the main etiology at the time of WL registration(490/1194 patients, 41%). HCV-related cirrhosis significantly decreased as indication to WL registration after DAA introduction(from 43.3% in 2006-2013 to 37.2% in 2014-2017, P = 0.05), especially amongst decHCV(from 24.2% in 2006-2013 to 15.9% in 2014-2017, P = 0.007). Even HCV remained the most common indication to LT over time(289/666, 43.4%), there was a trend towards a decrease after DAAs introduction(from 46.3% in 2006-2013 to 39% in 2014-2017, P = 0.06). HCV patients(M/F: 43/11, mean age: 57.7 ± 8 years) who achieved viral eradication in the WL had better transplant-free survival(log-rank test P = 0.02) and delisting rate(P = 0.002) than untreated HCV patients. CONCLUSION Introduction of DAAs significantly reduced WL registrations for HCV related cirrhosis, especially in the setting of decompensated cirrhosis. | Alberto Ferrarese Giacomo Germani Martina Gambato Francesco Paolo Russo Marco Senzolo Alberto Zanetto Sarah Shalaby Umberto Cillo Giacomo Zanus Paolo Angeli Patrizia Burra | 2018 | World Journal of Gastroenterology2018，24，38： | 5 |
| 5 | Laparoscopic treatment of simple hepatic cysts and polycystic liver disease显示文摘 | P. Fiamingo U. Tedeschi M. Veroux U. Cillo A. Brolese A. Da Rold C. Madia G. Zanus D.F. D'Amico | 2003 | Surgical Endoscopy2003，，4： | 2 |
| 6 | Complications of Microwave Ablation for Liver Tumors: Results of a Multicenter Study显示文摘 | Tito Livraghi Franca Meloni Luigi Solbiati Giorgio Zanus | 2012 | CardioVascular and Interventional Radiology2012，，4： | 2 |
| 7 | Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries显示文摘 | U. Baccarani P. Piselli D. Serraino G.L. Adani D. Lorenzin M. Gambato A. Buda G. Zanus A. Vitale A. De Paoli C. Cimaglia V. Bresadola P. Toniutto A. Risaliti U. Cillo F. Bresadola P. Burra | 2009 | Digestive and Liver Disease2009，，1： | 2 |
| 8 | Prospective validation of the Barcelona Clinic Liver Cancer staging system显示文摘 | Umberto Cillo Alessandro Vitale Francesco Grigoletto Fabio Farinati Alberto Brolese Giacomo Zanus Daniele Neri Patrizia Boccagni Nela Srsen Francesco D’Amico Francesco Antonio Ciarleglio Alessio Bridda Davide Francesco D’Amico | 2006 | Journal of Hepatology2006，，4： | 2 |
| 9 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 2 |
| 10 | Risk Factors in Liver Retransplantation: A Single-Center Experience显示文摘 | C. Crivellin E. De Martin G. Germani M. Gambato M. Senzolo F.P. Russo A. Vitale G. Zanus U. Cillo P. Burra | 2011 | Transplantation Proceedings2011，，4： | 1 |
| 11 | Laparoscopic treatment of simple hepatic cysts and polycystic liver disease显示文摘 | P. Fiamingo U. Tedeschi M. Veroux U. Cillo A. Brolese A. Da Rold C. Madia G. Zanus D.F. D’Amico | 2003 | Surgical Endoscopy2003，，4： | 1 |
| 12 | Possibilities of using morin-ga(Moringa oleifera)leaf meal as a partial substitute for fishmeal in broil-er chickens diets显示文摘 | ZANU H K ASIEDU P TAMPUORI M | 2012 | Journal of Animal and Feed Research2012，2，1： | 1 |
| 13 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 1 |
| 14 | Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases显示文摘 | G. Zanus R. Boetto E. Gringeri A. Vitale F. D’Amico A. Carraro D. Bassi P. Bonsignore G. Noaro C. Mescoli M. Rugge P. Angeli M. Senzolo P. Burra P. Feltracco U. Cillo | 2011 | Transplantation Proceedings2011，，4： | 1 |
| 15 | 巴塞罗那临床肝癌分期与肝细胞癌患者肝移植术后的生存益处:一项多中心、队列研究显示文摘目的巴塞罗那临床肝癌(Barcelona ClinicLiver Cancer,BCLC)分期是评估肝癌预后的重要分期系统,其主要依据患者的健康状况、肿瘤特征(包括肿瘤分期与Okuda分期)及肝功能划分为5期,即:0期(非常早期)、A期(早期)、B期(中期)、C期(晚期)与D期(终末期)。基于BCLC分期系统,实施肝移植术应优先选择未接受肝移植的预后最差者,即BCLCD期,其次应选择BCLCB~C期,而BCLC0~A期患者因可从其他治疗手段中获益,故优先权最小。 | Vitale A Morales RR Zanus G 刘嘉 | 2011 | 中国肿瘤外科杂志2011，3，4： | 1 |
| 16 | Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation显示文摘 | Alessandro Vitale Francesco D’Amico Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Daniele Neri Amedeo Carraro Francesco Enrico D’Amico Patrizia Burra Francesco Russo Paolo Angeli Umberto Cillo | 2010 | Annals of Surgical Oncology2010，，9： | 1 |
| 17 | The survival benefit of liver transplantation in hepatocellular carcinoma patients显示文摘 | Umberto Cillo Alessandro Vitale Michael L. Volk Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Francesco D’Amico Fabio Farinati Patrizia Burra Francesco Russo Paolo Angeli Davide F. D’Amico | 2010 | Digestive and Liver Disease2010，，9： | 1 |
| 18 | Alcohol Abuse and De Novo Tumors in Liver Transplantation显示文摘 | G. Zanus A. Carraro A. Vitale E. Gringeri F. D’Amico M. Valmasoni F.E. D’Amico A. Brolese P. Boccagni D. Neri N. Srsen P. Burra P. Feltracco P. Bonsignore M. Scopelliti U. Cillo | 2009 | Transplantation Proceedings2009，，4： | 1 |
| 19 | Complications of Microwave Ablation for Liver Tumors: Results of a Multicenter Study显示文摘 | Tito Livraghi Franca Meloni Luigi Solbiati Giorgio Zanus | 2012 | CardioVascular and Interventional Radiology2012，，4： | 1 |
| 20 | Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation显示文摘 | A. Vitale M.L. Volk M. Gambato G. Zanus F. D’Amico A. Carraro A. Pauletto P. Bonsignore M. Scopelliti M. Polacco F. Russo M. Senzolo P. Burra A. Romano P. Angeli U. Cillo | 2010 | Transplantation Proceedings2010，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员